Evidence supporting the use of: N-Acetyl Cysteine
For the health condition: Emphysema

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

N-Acetyl Cysteine (NAC) has been investigated as a supportive treatment for emphysema and other chronic obstructive pulmonary diseases (COPD), primarily due to its mucolytic (mucus-thinning) and antioxidant properties. Mechanistically, NAC serves as a precursor to glutathione, a major antioxidant in lung tissue, and helps reduce oxidative stress—a key factor in the progression of emphysema. Additionally, by breaking disulfide bonds in mucus glycoproteins, NAC makes respiratory secretions less viscous, potentially aiding in airway clearance.

Numerous clinical studies and meta-analyses have explored NAC's effects in COPD patients, some of whom have emphysema. A 2015 Cochrane Review and several randomized controlled trials found that long-term oral NAC at moderate to high doses (typically 600-1200 mg/day) can reduce the frequency of exacerbations in COPD. However, improvements in lung function (such as FEV1), quality of life, or symptoms are inconsistent, and effects specifically in emphysema are less robustly demonstrated compared to the broader COPD population.

Current clinical guidelines vary in their recommendations, often suggesting NAC as a possible adjunct in patients with frequent exacerbations despite standard care. Nevertheless, the evidence is not strong enough to support NAC as a primary treatment for emphysema, and its benefit appears modest. Thus, while there is a scientific rationale and some clinical validation, the overall evidence remains limited (rated 2/5), and NAC should not replace established therapies.

More about N-Acetyl Cysteine
More about Emphysema

Products containing N-Acetyl Cysteine

We currently have no products on Vitabase that contain this ingredient.